ESTRO 2021 Abstract Book

S631

ESTRO 2021

All scores and data were collated and analysed in SPSS. The mean scores between phases and RTTs were assessed and compared used Mann-Whitney U and Kruskal-Wallis tests.

Results A total of 116 events were assessed, 37 from Phase 1 and 79 from Phase 2. Four events were removed as they were deemed to be non-prescribing events. The mean overall total score from prescribing events in Phase 1 was 51.75% and in Phase 2 was 56.75%, with no statistical significance in the difference ( P =.339). The mean inter-variability score was 54.72% and the intra-variability score was 56.02%, with no significant difference ( P =.914). The scoring by each RTTs on their colleagues prescribing event showed no statistical difference ( P =.872). However, the overall score achieved of each RTT was significantly different ( P <.0001), Table 1. Of note from Phase 1 to 2 RTT 2 and 4s scores decreased in contrast to RTT 1 and 3’s whose scores increased, Table 1.

Conclusion From the results the overall prescribing scores appear to be improving from Phase 1 to 2; however, this finding is not statistically significant. RTTs are scoring their colleagues similar to themselves, with no difference seen in inter and intra-variability scores. However, there is a difference in the scores achieved by different RTTs, e.g. RTT 4 achieved the highest overall score of 74.99%. The decrease in the mean score for Radiographer 2 and 4 has been addressed one-to-one. With no guidance in auditing prescribing practice, the overall score achieved by RTT 4 will be utilised as the gold-standard score to achieve in future phases of this project, and training and guidance will be provided to enable RTTs to achieve this score. The next step is to undertake Phase 3 on RTTs. For Phase 4 the scoring tool will incorporate feedback from Oncologists and will be performed on RTTs, Nurses, Pharmacists and Oncologists. PD-0797 Large scale implementation of standardized neurocognitive testing in clinical routine practice C. Offermann 1 , C. Zegers 1 , J. Dijkstra 2 , F. Hoebers 3 , I. Compter 4 , D. de Ruysscher 1 , M. Anten 5 , W. van Elmpt 6 , D. Eekers 6 1 Maastro clinic, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands; 2 MUMC+, Department of Clinical Psychology Maastricht University Medical Center+, Maastricht, The Netherlands; 3 Maastro clinic, Department of Radiation Oncology (Maastro), Maasticht, The Netherlands; 4 Maastro, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands; 5 MUMC, Departement of